RADNOR, Pa., Feb. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Chang v. Neumora Therapeutics, Inc., allows purchasers of Neumora's common stock from its IPO on September 15, 2023, to seek lead plaintiff status until April 7, 2025 [1][5]. - The lawsuit alleges that Neumora and its executives misled investors regarding the efficacy of its flagship therapeutic candidate, Navacaprant, particularly in relation to its Phase Two and Phase Three clinical trials [2][3]. Group 2: Financial Impact - Neumora's IPO involved the sale of 14.7 million shares at a price of $17.00 per share [2]. - Following the announcement of the KOASTAL-1 study results on January 2, 2025, which failed to show significant improvement in depression treatment, Neumora's stock price plummeted to $1.91 per share, marking an 88.7% decline from the IPO price [4]. Group 3: Allegations Against Neumora - The lawsuit claims that Neumora altered the Phase Two Trial criteria to include a broader patient population to support its claims of Navacaprant's effectiveness [3]. - It is alleged that the Phase Two Trials lacked sufficient data, particularly regarding patient demographics, which undermined the reliability of the study results [3]. Group 4: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, highlighting its track record in securing monetary relief for investors in securities fraud cases [6].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1][2]. Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study accurately [2]. Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [4]. - The firm encourages Neumora investors who have suffered significant losses to contact them for more information [4].

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=128956&from=4CLASS PERIOD: T ...

LOS ANGELES, Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ: NMRA) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the ...

ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against (“Neumora” or the “Company”) (NASDAQ: NMRA) on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to its September 15, 2023 initial public offering (the “IPO”), and who were damaged thereby. The lawsuit alleges that certain documents issued in connection with the IPO were inaccurate and misleading, contained inaccurate and misleading ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

SAN DIEGO, Feb. 10, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023.  Neumora is a clinical-stage biopharmaceutical company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800 ...